Botensilimab

Botensilimab (AGEN1181) is a monoclonal antibody developed by Agenus. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: Botensilimab is an Fc-enhanced anti-CTLA-4 monoclonal antibody designed to prime a broader anti-tumour immune response, typically studied in combination with balstilimab (anti-PD-1). ClinicalTrials.gov describes the intervention as: An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT05608044, plans to enrol 234 participants (actual) with primary completion expected 2027-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.